Ariel Miller

List of Publications by Year
in descending order

125 papers	8,308 citations	50276 46 h-index	48315 88 g-index
130 all docs	130 docs citations	130 times ranked	9060 citing authors

#	Article	IF	Citations
1	Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses. Frontiers in Immunology, 2022, 13, 868915.	4.8	32
2	Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis. BMC Neurology, 2021, 21, 136.	1.8	10
3	Concordance Between Persons with Multiple Sclerosis and Treating Physician on Medication Effects and Health Status. Patient Preference and Adherence, 2021, Volume 15, 939-943.	1.8	3
4	Mobile-phone-based e-diary derived patient reported outcomes: Association with clinical disease activity, psychological status and quality of life of patients with multiple sclerosis. PLoS ONE, 2021, 16, e0250647.	2.5	6
5	Mobile phone-based e-diary for assessment and enhancement of medications adherence among patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732093930.	1.0	7
6	Multiple modality approach to assess adherence to medications across time in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2020, 40, 101951.	2.0	7
7	Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS. Journal of Neuroimmunology, 2020, 343, 577230.	2.3	9
8	HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731988272.	1.0	10
9	Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire. Multiple Sclerosis and Related Disorders, 2019, 34, 29-37.	2.0	22
10	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	3.0	101
11	Dimethyl fumarate as a first- vs second-line therapy in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e508.	6.0	11
12	Effector and regulatory B cells in Multiple Sclerosis. Clinical Immunology, 2017, 184, 11-25.	3.2	64
13	Methylome and transcriptome profiling in Myasthenia Gravis monozygotic twins. Journal of Autoimmunity, 2017, 82, 62-73.	6.5	23
14	Sodium intake and multiple sclerosis activity and progression in <scp>BENEFIT</scp>. Annals of Neurology, 2017, 82, 20-29.	5.3	80
15	Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. ACS Nano, 2017, 11, 112-125.	14.6	386
16	Exhaled Breath Markers for Nonimaging and Noninvasive Measures for Detection of Multiple Sclerosis. ACS Chemical Neuroscience, 2017, 8, 2402-2413.	3.5	43
17	Personalized Medicine and Theranostics. , 2016, , 387-414.		1
18	Cognitive Function of Patients with CrohnÊ¼s Disease is Associated with Intestinal Disease Activity. Inflammatory Bowel Diseases, 2016, 22, 364-371.	1.9	17

#	Article	IF	Citations
19	Shifting paradigms in multiple sclerosis. Current Opinion in Neurology, 2016, 29, 354-361.	3.6	12
20	Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFÎ² in patients with Multiple Sclerosis. Journal of Autoimmunity, 2016, 70, 40-51.	6.5	69
21	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology, 2016, 87, 446-446.	1.1	0
22	Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis. Journal of the Neurological Sciences, 2016, 360, 102-109.	0.6	21
23	Integrative analysis of methylome and transcriptome in human blood identifies extensive sex- and immune cell-specific differentially methylated regions. Epigenetics, 2015, 10, 943-957.	2.7	57
24	Gene Expression Profiling of the Response to Interferon Beta in Epstein-Barr-Transformed and Primary B Cells of Patients with Multiple Sclerosis. PLoS ONE, 2014, 9, e102331.	2.5	21
25	<scp>VAV</scp>1 and <scp>BAFF</scp>, via <scp>NF</scp>ÎºB pathway, are genetic risk factors for myasthenia gravis. Annals of Clinical and Translational Neurology, 2014, 1, 329-339.	3.7	27
26	T cells from autoimmune patients display reduced sensitivity to immunoregulation by mesenchymal stem cells: Role of IL-2. Autoimmunity Reviews, 2014, 13, 187-196.	5.8	37
27	Revised diagnostic criteria of multiple sclerosis. Autoimmunity Reviews, 2014, 13, 518-524.	5.8	238
28	Integrative analysis of DNA methylation and gene expression identifies distinct profiles among immune cells subsets. Journal of Neuroimmunology, 2014, 275, 67-68.	2.3	0
29	The immune-modulatory effects of fingolimod on phenotype and function of B cells from patients with Multiple Sclerosis. Journal of Neuroimmunology, 2014, 275, 214.	2.3	0
30	Genetic basis of myasthenia gravis â€“ A comprehensive review. Journal of Autoimmunity, 2014, 52, 146-153.	6.5	98
31	Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology, 2013, 13, 60.	1.8	72
32	The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. Brain, Behavior, and Immunity, 2013, 32, 180-185.	4.1	51
33	Interferon-Beta Induces Distinct Gene Expression Response Patterns in Human Monocytes versus T cells. PLoS ONE, 2013, 8, e62366.	2.5	33
34	Telemedicine for multiple sclerosis patients: assessment using Health Value Compass. Multiple Sclerosis Journal, 2012, 18, 472-480.	3.0	36
35	Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis. Expert Review of Neurotherapeutics, 2012, 12, 343-352.	2.8	39
36	Multiple sclerosis in diverse populations: characteristics in distinct Arab ethnicities in Israel. Multiple Sclerosis Journal, 2012, 18, 1737-1744.	3.0	11

#	Article	IF	Citations
37	Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis. Journal of Neuroimmunology, 2012, 251, 45-54.	2.3	55
38	Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. Journal of the Neurological Sciences, 2012, 314, 37-40.	0.6	98
39	The ubiquitinâ€“proteasome pathway regulates claudin 5 degradation. Journal of Cellular Biochemistry, 2012, 113, 2415-2423.	2.6	55
40	Tight junction proteins expression and modulation in immune cells and multiple sclerosis. Journal of Cellular and Molecular Medicine, 2012, 16, 765-775.	3.6	35
41	Aberrant expression of the apoptosis-related proteins BAK and MCL1 in T cells in multiple sclerosis. Journal of Neuroimmunology, 2012, 244, 51-56.	2.3	10
42	Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments. Expert Review of Neurotherapeutics, 2011, 11, 1077-1088.	2.8	106
43	Detection of Multiple Sclerosis from Exhaled Breath Using Bilayers of Polycyclic Aromatic Hydrocarbons and Single-Wall Carbon Nanotubes. ACS Chemical Neuroscience, 2011, 2, 687-693.	3.5	113
44	Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis. Journal of Cellular and Molecular Medicine, 2011, 15, 2421-2429.	3.6	53
45	Cathepsins (S and B) and their inhibitor Cystatin C in immune cells: Modulation by interferon-Î² and role played in cell migration. Journal of Neuroimmunology, 2011, 232, 200-206.	2.3	35
46	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology, The, 2011, 10, 745-758.	10.2	247
47	Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmunity Reviews, 2011, 10, 410-415.	5.8	148
48	Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics. EPMA Journal, 2010, 1, 317-327.	6.1	8
49	Involvement of phosphodiesterases in autoimmune diseases. Journal of Neuroimmunology, 2010, 220, 43-51.	2.3	10
50	Opposing effects of the HLA-DRB1*0301-DQB1*0201 haplotype on the risk for multiple sclerosis in diverse Arab populations in Israel. Genes and Immunity, 2010, 11, 423-431.	4.1	21
51	Patients with multiple sclerosis in a war zone: coping strategies associated with reduced risk for relapse. Multiple Sclerosis Journal, 2010, 16, 463-471.	3.0	21
52	Internet Usage by Patients with Multiple Sclerosis: Implications to Participatory Medicine and Personalized Healthcare. Multiple Sclerosis International, 2010, 2010, 1-7.	0.8	56
53	Glide-symmetric locomotion reinforcement in patients with multiple sclerosis by visual feedback. Disability and Rehabilitation: Assistive Technology, 2010, 5, 323-326.	2.2	11
54	Home-based personalized cognitive training in MS patients: A study of adherence and cognitive performance. NeuroRehabilitation, 2010, 26, 143-153.	1.3	94

#	Article	IF	Citations
55	Mediterranean Weather Conditions and Exacerbations of Multiple Sclerosis. Neuroepidemiology, 2010, 35, 142-151.	2.3	14
56	Theranostics and Translation toward Personalized Medicine for Multiple Sclerosis. , 2010, , 205-254.		2
57	Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses. Journal of Neuroimmunology, 2009, 210, 124-127.	2.3	17
58	198-P: HLA immunogenetics of multiple sclerosis in Israeli arabs. Human Immunology, 2009, 70, S111.	2.4	0
59	ME7 Optimizing Therapeutics for Multiple Sclerosis Patients. Clinical Neurophysiology, 2009, 120, S21.	1.5	0
60	Goal disengagement and goal re-engagement among multiple sclerosis patients: Relationship to well-being and illness representation. Psychology and Health, 2009, 24, 175-186.	2.2	28
61	Effects of Dextromethorphan/Quinidine on Auditory Event-Related Potentials in Multiple Sclerosis Patients With Pseudobulbar Affect. Journal of Clinical Psychopharmacology, 2009, 29, 444-452.	1.4	15
62	Impact of exposure to war stress on exacerbations of multiple sclerosis. Annals of Neurology, 2008, 64, 143-148.	5.3	56
63	Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect. Journal of the Neurological Sciences, 2008, 271, 137-147.	0.6	30
64	New immunosuppressive approaches: Oral administration of CD3-specific antibody to treat autoimmunity. Journal of the Neurological Sciences, 2008, 274, 9-12.	0.6	40
65	Translation towards personalized medicine in Multiple Sclerosis. Journal of the Neurological Sciences, 2008, 274, 68-75.	0.6	28
66	In vitro induction of regulatory T cells by anti-CD3 antibody in humans. Journal of Autoimmunity, 2008, 30, 21-28.	6.5	45
67	Chronotherapy using corticosteroids for multiple sclerosis relapses. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 886-888.	1.9	34
68	Sexual dysfunction in females with multiple sclerosis: quantitative sensory testing. Multiple Sclerosis Journal, 2007, 13, 95-105.	3.0	68
69	Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenetics and Genomics, 2007, 17, 657-666.	1.5	74
70	Auditory feedback control for improvement of gait in patients with Multiple Sclerosis. Journal of the Neurological Sciences, 2007, 254, 90-94.	0.6	68
71	Separation-individuation processes of adolescent children of parents with multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 87-94.	3.0	23
72	Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Current Medical Research and Opinion, 2007, 23, 2823-2832.	1.9	7

#	Article	IF	Citations
73	Therapeutic use of dextromethorphan: Key learnings from treatment of pseudobulbar affect. Journal of the Neurological Sciences, 2007, 259, 67-73.	0.6	8
74	Virtual reality cues for improvement of gait in patients with multiple sclerosis. Neurology, 2006, 66, 178-181.	1.1	111
75	Pseudobulbar affect in multiple sclerosis: Toward the development of innovative therapeutic strategies. Journal of the Neurological Sciences, 2006, 245, 153-159.	0.6	20
76	Serum anti-Glc(Î±1,4)Glc(Î±) antibodies as a biomarker for relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2006, 244, 59-68.	0.6	58
77	Emerging therapeutic targets in multiple sclerosis. Current Opinion in Neurology, 2006, 19, 260-266.	3.6	25
78	A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. European Journal of Neurology, 2006, 13, 61-71.	3.3	46
79	Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25â^'LAP+ T cells. Nature Medicine, 2006, 12, 627-635.	30.7	229
80	Health-related Quality of Life in Multiple Sclerosis: The Impact of Disability, Gender and Employment Status. Quality of Life Research, 2006, 15, 259-271.	3.1	243
81	Cytokine-mediated modulation of MMPs and TIMPs in multipotential neural precursor cells. Journal of Neuroimmunology, 2006, 175, 12-18.	2.3	33
82	Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Annals of Neurology, 2006, 59, 780-787.	5.3	183
83	Multiple sclerosis frequency in Israelâ€™s diverse populations. Neurology, 2006, 66, 1061-1066.	1.1	53
84	Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis. International Immunology, 2006, 18, 1355-1362.	4.0	12
85	Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. Journal of Neuroimmunology, 2005, 163, 157-164.	2.3	71
86	Emotional responses of children and adolescents to parents with multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 464-468.	3.0	36
87	Hypoxia of endothelial cells leads to MMP-2-dependent survival and death. American Journal of Physiology - Cell Physiology, 2005, 289, C1321-C1331.	4.6	79
88	Matrix Metalloproteinase-9, Its Tissue Inhibitor(TIMP)-1 and CRP in Alzheimerâ€™s Disease. European Neurology, 2005, 53, 155-157.	1.4	10
89	Health-related quality of life in multiple sclerosis: psychometric analysis of inventories. Multiple Sclerosis Journal, 2005, 11, 450-458.	3.0	35
90	Vitamin B12, demyelination, remyelination and repair in multiple sclerosis. Journal of the Neurological Sciences, 2005, 233, 93-97.	0.6	132

#	Article	IF	Citations
91	Cognitive strategies application of multiple sclerosis patients. Multiple Sclerosis Journal, 2004, 10, 67-73.	3.0	31
92	Genomic profiling of interpopulation diversity guides prioritization of candidate-genes for autoimmunity. Genes and Immunity, 2004, 5, 493-504.	4.1	10
93	Bio-markers of disease activity and response to therapy in multiple sclerosis. Clinical Neurology and Neurosurgery, 2004, 106, 249-254.	1.4	31
94	The 'Immunological-Synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-Î². Journal of Neuroimmunology, 2003, 144, 116-124.	2.3	36
95	Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis. Journal of the Neurological Sciences, 2003, 206, 43-48.	0.6	37
96	The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. International Immunology, 2002, 14, 1449-1457.	4.0	45
97	Regulation of Endothelial Matrix Metalloproteinase-2 by Hypoxia/Reoxygenation. Circulation Research, 2002, 90, 784-791.	4.5	157
98	Immunological indicators of disease activity and prognosis in multiple sclerosis. Current Opinion in Neurology, 2002, 15, 233-237.	3.6	20
99	Multiple sclerosis: from basic immunopathology to immune intervention. Clinical Neurology and Neurosurgery, 2002, 104, 172-176.	1.4	4
100	Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-Î³ and -Î²: implications to multiple sclerosis. Journal of Neuroimmunology, 2002, 131, 191-200.	2.3	26
101	Inorganic lead enhances cytokine-induced elevation of matrix metalloproteinase MMP-9 expression in glial cells. Journal of Neuroimmunology, 2002, 132, 123-128.	2.3	17
102	Pharmacogenetic development of personalized medicine: Multiple sclerosis treatment as a model. Drug News and Perspectives, 2002, 15, 558.	1.5	12
103	Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferonâ€Î² therapy in relapsing and secondaryâ€progressive multiple sclerosis patients. Annals of Neurology, 2001, 50, 443-451.	5.3	117
104	Modulation of Human Leukocyte Antigen and Intracellular Adhesion Moleculeâ€"1 Surface Expression in Malignant and Nonmalignant Human Thyroid Cells by Cytokines in the Context of Extracellular Matrix. Thyroid, 2000, 10, 945-950.	4.5	5
105	Treatment of multiple sclerosis with Copolymer-1 (CopaxoneÂ®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. Journal of Neuroimmunology, 1998, 92, 113-121.	2.3	226
106	Matrix-Metalloproteinases (MMPS) in Astroglial Cells. Advances in Behavioral Biology, 1998, , 149-157.	0.2	0
107	Immunoregulatory effects of interferon-Î² and interacting cytokines on human vascular endothelial cells implications for multiple sclerosis and other autoimmune diseases. Journal of Neuroimmunology, 1996, 64, 151-161.	2.3	63
108	Soluble tumor necrosis factor receptors reduce bowel ischemia-induced lung permeability and neutrophil sequestration. Critical Care Medicine, 1995, 23, 1377-1381.	0.9	66

#	Article	IF	Citations
109	Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals. European Journal of Immunology, 1994, 24, 1026-1032.	2.9	110
110	Antigen-driven tissue-specific suppression following oral tolerance: Orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. European Journal of Immunology, 1994, 24, 2104-2109.	2.9	128
111	Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens. Annual Review of Immunology, 1994, 12, 809-837.	21.8	878
112	The Epigenetics of Multiple Sclerosis: Clues to Etiology and a Rationale for Immune Therapy. Annual Review of Neuroscience, 1994, 17, 247-265.	10.7	19
113	Functional Interactions of Fibronectin and TNFÎ±: A Paradigm of Physiological Linkage Between Cytokines and Extracellular Matrix Moieties. Cell Adhesion and Communication, 1994, 2, 269-273.	1.7	15
114	Physically Damaged Extracellular Matrix Induces TNF-alpha Secretion by Interacting Resting CD4+ T Cells and Macrophages. Scandinavian Journal of Immunology, 1993, 37, 111-115.	2.7	35
115	Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization. Journal of Neuroimmunology, 1993, 46, 73-82.	2.3	50
116	Differential effects of proclatic upon activation and differentiation of human B lymphocytes. Journal of Neuroimmunology, 1993, 47, 35-40.	2.3	73
117	Suppression of Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens. , 1993, , 627-634.		5
118	Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 421-425.	7.1	706
119	Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. V. Hierarchy of suppression by myelin basic protein from different species. Journal of Neuroimmunology, 1992, 39, 243-250.	2.3	64
120	T lymphocyte adhesion to the fibronectin and laminin components of the extracellular matrix is regulated by the CD4 molecule. European Journal of Immunology, 1992, 22, 7-13.	2.9	24
121	Antigen-Driven Peripheral Immune Tolerance.. Annals of the New York Academy of Sciences, 1991, 636, 227-232.	3.8	29
122	Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases. FASEB Journal, 1991, 5, 2560-2566.	0.5	44
123	Immunotherapy in autoimmune diseases. Current Opinion in Immunology, 1991, 3, 936-940.	5.5	13
124	Antigen-driven bystander suppression after oral administration of antigens.. Journal of Experimental Medicine, 1991, 174, 791-798.	8.5	436
125	Cimetidine as an immunomodulator in the treatment of herpes zoster. Journal of Neuroimmunology, 1989, 22, 69-76.	2.3	10